PACS Group Reports Strong FY2025 Results with 29.3% Revenue Growth and Positive 2026 Outlook
PACS has more than doubled off its 52-week low of $7.5.
Summary
PACS Group, a leading post-acute healthcare provider, announced robust financial results for fiscal year 2025, including a 29.3% increase in revenue and a significant rise in net income, alongside optimistic guidance for 2026.
Key Events · Earnings and Guidance · PACS
-
Strong FY2025 Financial Performance
Full-year 2025 revenue increased 29.3% to $5.29 billion, with net income rising to $191.5 million and Adjusted EBITDA reaching $505.0 million.
-
Positive FY2026 Guidance
The company projects full-year 2026 revenue between $5.65 billion and $5.75 billion, and Adjusted EBITDA between $555 million and $575 million, indicating continued growth.
-
Operational Excellence and Expansion
PACS Group reported 73.4% of its skilled nursing facilities achieved 4 or 5-star CMS Quality Measure ratings and mature facilities maintained 94.9% occupancy, significantly above the industry average. The company also added 8 operating facilities in 2025.
Analysis · PACS · Industrial Applications And Services
The filing details PACS Group's strong financial performance for the full year 2025, marked by substantial revenue and net income growth, driven by operational excellence and strategic expansion. The company's positive outlook for 2026, including projected revenue and Adjusted EBITDA increases, suggests continued momentum. These results, coupled with high occupancy rates and quality ratings, reinforce the company's strong market position in the post-acute healthcare sector.
At the time of this filing, PACS was trading at $41.67 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $7.50 to $43.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.